Urinary urgency outcomes after propiverine treatment for an overactive bladder: the 'Propiverine study on overactive bladder including urgency data'

被引:31
|
作者
Lee, Kyu-Sung [12 ]
Lee, Hye Won [12 ]
Choo, Myung-Soo [11 ]
Paick, Jae-Seung [10 ]
Lee, Jeong Gu [9 ]
Seo, Ju Tae [8 ]
Lee, Jeong Zoo [2 ]
Lee, Young-Suk [12 ]
Yoon, Hana [7 ]
Park, Choal Hee [3 ]
Na, Yong-Gil [4 ]
Jeong, Young Beom [5 ]
Lee, Jong Bouk [1 ]
Park, Won Hee [6 ]
机构
[1] Natl Med Ctr, Seoul, South Korea
[2] Pusan Natl Univ, Coll Med, Pusan 609735, South Korea
[3] Keimyung Univ, Sch Med, Taegu, South Korea
[4] Chungnam Natl Univ, Coll Med, Taejon, South Korea
[5] Chonbuk Natl Univ, Sch Med, Jeonju, South Korea
[6] Inha Univ, Coll Med, Inchon, South Korea
[7] Ewha Womans Univ, Sch Med, Seoul, South Korea
[8] Kwandong Univ, Coll Med, Seoul, South Korea
[9] Korea Univ, Coll Med, Seoul 136705, South Korea
[10] Seoul Natl Univ, Coll Med, Seoul, South Korea
[11] Univ Ulsan, Coll Med, Seoul, South Korea
[12] Sungkyunkwan Univ, Dept Urol, Samsung Med Ctr, Sch Med, Seoul, South Korea
关键词
overactive bladder; urinary urgency; propiverine hydrochloride; randomized trial; DOUBLE-BLIND; INCONTINENCE; SYMPTOMS; TOLERABILITY; TOLTERODINE; SOLIFENACIN; PERCEPTION; EFFICACY; TRIAL;
D O I
10.1111/j.1464-410X.2009.09050.x
中图分类号
R5 [内科学]; R69 [泌尿科学(泌尿生殖系疾病)];
学科分类号
1002 ; 100201 ;
摘要
OBJECTIVE To investigate the effects of a daily regimen of propiverine 20 mg in patients with an overactive bladder (OAB), focused on improving urgency, as the clinical efficacy of treatment for OAB should be measured in terms of urgency, the cornerstone symptom of OAB. PATIENTS AND METHODS Eligible patients aged >= 18 years with symptoms of OAB were enrolled in this multicentre, prospective, parallel, double-blind, placebo-controlled trial. Of 264 patients (mean age 52.2 years), 221 who had efficacy data available from baseline and at least one on-treatment visit with > 75% compliance with medication were analysed (142 in the propiverine group and 79 in the placebo group). All patients were randomized to receive a placebo or 20 mg propiverine once daily in a 12-week study. They completed a 3-day voiding diary before visits during the study period, including the severity of urgency associated with every voiding, using the Indevus Urgency Severity Scale and the Urgency Perception Score. The patients' overall self-evaluation of treatment benefits at the end of the study, and safety data, were also collected. RESULTS The daily urgency episodes reduced significantly from baseline to 12 weeks on propiverine treatment, compared with placebo (-46.0% vs -31.3%, P = 0.005). Secondary endpoints, including sum of urgency severity per 24 h, urgency severity per void, and daytime voiding frequency, were also improved significantly in the propiverine group. Overall, of those patients treated with propiverine, 38.7% rated their treatment as providing 'much benefit', compared with 15.2% of the placebo group (P = 0.025). Adverse events reported by 32 (22.5%) and 10 (12.7%) patients in the propiverine and placebo group were all tolerable. However, this is a short-term study using only one fixed regimen. CONCLUSIONS Propiverine 20 mg once-daily could be an effective treatment for patients with OAB, by improving urgency.
引用
收藏
页码:1565 / 1570
页数:6
相关论文
共 50 条
  • [1] Does urinary urgency drive urinary frequency in overactive bladder?
    Versi, Eboo
    Rovner, Eric S.
    Dmochowski, Roger R.
    Tu, Le Mai
    De Wachter, Stefan
    LUTS-LOWER URINARY TRACT SYMPTOMS, 2022, 14 (04) : 242 - 247
  • [2] Efficacy and Safety of Propiverine in Children with Overactive Bladder
    Kim, Woo Jung
    Lee, Dong-Gi
    Lee, Sang Wook
    Lee, Yoon Kyung
    Lee, Jae Seung
    Park, Kwan Hyun
    Baek, Minki
    KOREAN JOURNAL OF UROLOGY, 2012, 53 (04) : 275 - 279
  • [3] Urinary urgency: a review of its assessment as the key symptom of the overactive bladder syndrome
    Abrams, Paul
    Chapple, Christopher R.
    Juenemann, Klaus-Peter
    Sharpe, Steven
    WORLD JOURNAL OF UROLOGY, 2012, 30 (03) : 385 - 392
  • [4] Efficacy and Safety of Propiverine and Solifenacin for the Treatment of Female Patients with Overactive Bladder: A Crossover Study
    Wada, Naoki
    Watanabe, Masaki
    Kita, Masafumi
    Osanai, Hiroaki
    Yamaguchi, Satoshi
    Numata, Atsushi
    Kakizaki, Hidehiro
    LUTS-LOWER URINARY TRACT SYMPTOMS, 2011, 3 (01) : 36 - 42
  • [5] Total urgency and frequency score as a measure of urgency and frequency in overactive bladder and storage lower urinary tract symptoms
    Chapple, Christopher R.
    Drake, Marcus J.
    Van Kerrebroeck, Philip
    Cardozo, Linda
    Drogendijk, Ted
    Klaver, Monique
    Van Charldorp, Karin
    Hakimi, Zalmai
    Compion, Gerhard
    BJU INTERNATIONAL, 2014, 113 (05) : 696 - 703
  • [6] Overactive bladder and the definition of urgency
    Blaivas, Jerry G.
    NEUROUROLOGY AND URODYNAMICS, 2007, 26 (06) : 757 - 758
  • [7] Randomized, Single-Blind, Parallel Study of the Effectiveness and Safety of Solifenacin versus Propiverine in the Treatment of Overactive Bladder
    Fukuda, Takehiko
    Yamanishi, Tomonori
    Uchiyama, Tomoyuki
    Kamai, Takao
    LUTS-LOWER URINARY TRACT SYMPTOMS, 2013, 5 (01) : 11 - 16
  • [8] Therapy of overactive bladder with propiverine ER. Results of a non-interventional study with a propiverine retard formulation and comparison to clinical studies
    Kessler-Zumpe, P. L.
    Murgas, S.
    Neumann, G.
    Richter, A. E.
    UROLOGE, 2009, 48 (11): : 1346 - 1351
  • [9] Axonics® system for treatment of overactive bladder syndrome and urinary urgency incontinence
    Wang, Alice
    Rourke, Elizabeth
    Sebesta, Elisabeth
    Dmochowski, Roger
    EXPERT REVIEW OF MEDICAL DEVICES, 2021, 18 (08) : 727 - 732
  • [10] Propiverine versus tolterodine:: Efficacy and tolerability in patients with overactive bladder
    Jünemann, KP
    Halaska, M
    Rittstein, T
    Mürtz, G
    Schnabel, F
    Brünjes, R
    Nurkiewicz, W
    EUROPEAN UROLOGY, 2005, 48 (03) : 478 - 482